ProCE Banner Activity

Extended Follow-up Results From a Pilot Study of Brentuximab Vedotin + AVD in Newly Diagnosed, Early-Stage, Unfavorable-Risk cHL Using Baseline MTV and PET2 Evaluation

Slideset Download
Conference Coverage

With extended follow-up, short-course brentuximab vedotin + AVD remains highly active in early-stage, unfavorable-risk classical Hodgkin lymphoma.

Released: December 16, 2022

Expiration: December 15, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen